

We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

4,800

Open access books available

122,000

International authors and editors

135M

Downloads

Our authors are among the

154

Countries delivered to

TOP 1%

most cited scientists

12.2%

Contributors from top 500 universities



WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.

For more information visit www.intechopen.com



The Impact of Cardiometabolic Risk in Patients with Severe Mental Illness: From Evidence to Clinical Management

Guido Di Sciascio and Salvatore Calò

*Azienda Ospedaliero-Universitaria "Consortiale Policlinico" di Bari
Italy*

1. Introduction

People with severe mental illness have an excess burden of physical comorbidity and mortality, especially due to cardiovascular illness, compared to persons without psychiatric disorders. Individuals with schizophrenia and bipolar disorder have an increased risk for obesity, type 2 diabetes, and other cardiometabolic risk factors but they usually receive inconsistent and insufficient physical monitoring and management. There is a wide array of variables that may potentially contribute to the increased comorbidity and mortality rates associated with major mental disorders and this is partly related to lifestyle factors such as poor diet, lack of exercise and smoking.

A final important source of cardiometabolic risk in major mental disorders is treatment itself although before the introduction of the antipsychotic drugs it was acknowledged that patients with schizophrenia and bipolar disorder may be at a higher risk of abnormal glucose metabolism and metabolic disorders compared to general population. The reasons for this difference may include an inherent increased risk of diabetes associated with the illness itself and an increased metabolic risk related to behaviors having a negative impact on health.

Although the main aim of the treatment of severe mental illness is to control psychotic symptoms and enable patients to function as normally as possible it is really important to considerer in choosing a treatment the impact on physical as well as mental health. The safety and tolerability of psychotropic drugs are especially important because of the chronicity of the illnesses being treated, the need for long-term therapy and the poor insight and motivation of many of the patients. The occurrence of side effects determines not only a reduction of the physical health of patients as a whole but also a reduction of compliance and we know that sub-optimal adherence to psychotropic medication, in particular antipsychotics, greatly increases the risk of relapse and rehospitalisation.

About antipsychotics, between-drug differences in efficacy are relatively modest for the atypicals, or between atypicals and conventionals, while differences in safety and tolerability are larger and more clinically relevant. The lower risk of extrapyramidal symptoms and tardive dyskinesia with atypical antipsychotics has allowed a greater focus on other physical health risks associated with these treatment. Antipsychotic drugs have side effects such as weight gain, lipid abnormalities and disturbance of glucose regulation

that increase the risk of the metabolic syndrome, a recognized cluster of features (hypertension, central obesity, glucose intolerance / insulin resistance and dyslipidaemia) that is predictive of both type-2 diabetes and atherosclerotic vascular disease.

About the side effect of antipsychotics, in the past few years, particular attention has been paid to the ability of these drugs to prolong the corrected QT (QTc) interval, which may result in torsades de pointes and sudden cardiac death. Other factors that could lead to QTc lengthening in psychotic patients are the presence of abnormalities in glucose metabolism and comorbid cardiovascular diseases which are increased in patients treated with antipsychotics.

These matters emphasize that cardiovascular safety of antipsychotic drugs is of paramount importance because patients diagnosed with schizophrenia, schizoaffective disorder, or bipolar disorder are at high risk to begin with.

All reviews of the association between psychotic illness, metabolic syndrome and antipsychotic medication point to the need for routine physical health screening of patients prescribed antipsychotic drugs, whatever the indication for such treatment. The maintenance of physical health is an important factor in the successful global management of these patients. For these reasons there is clearly a need for clinicians to employ multiple strategies to minimize metabolic risk in schizophrenia patients, including using metabolically more neutral medications, promoting healthier lifestyle habits, developing expertise in switching antipsychotics for metabolic reasons and, most importantly, practicing good preventive care through regular monitoring of metabolic parameters.

In recent years the importance of physical health in people with psychotic illness treated with antipsychotics has led to monitoring recommendations cosponsored by different associations (endocrinology, cardiology and psychiatry) in United States and in Europe although general health care needs in psychiatric population are commonly neglected and psychiatrists mainly focus on efficacy of treatment of psychotic symptoms.

The aim of this chapter is to evaluate the clinical importance of cardiometabolic risk factors among persons with mental disorders, addressing the contribution of antipsychotic medications to increased cardiometabolic risk, and suggesting monitoring strategies for modifiable risk factors relevant to the treatment of serious mental illness.

A Medline search was performed to examine published data from 1990 through June 2011.

The search included the following keywords: 'diabetes', 'weight gain', 'weight management', 'dyslipidaemia', 'metabolic syndrome', 'QTc interval', 'metabolic and cardiovascular risk', and were used interchangeably and were also combined in the search together with 'schizophrenia', 'bipolar disorder', 'severe mental illness' and 'antipsychotic drugs'.

Papers were included if they were published in English, with a diagnosis of schizophrenia or bipolar disorder and treatment with antipsychotic medication.

Studies were also included if the focus was on monitoring and improvement in metabolic profile through the application of different strategies, such as psychoeducational (exercise and dietary) interventions or switching patients to less metabolically offending medications.

2. The burden of cardiometabolic illness

Individuals with major mental disorder, including schizophrenia, bipolar disorder and schizoaffective disorder, are prone to many different physical health problems (De Hert et

al., 2011). While these diseases are also prevalent in the general population, their impact on individuals with major mental disorder is significantly greater (Maj, 2009). Subjects with major mental disorder tend to have more illnesses and a shorter lifespan than the general population, having a life expectancy that is approximately 20% shorter (Newman & Bland, 1991). Recently, a multistate study in U.S, supported by the Center for Mental Health Services in collaboration with the National Association of State Mental Health Program Directors, found that patients with serious mental illness lost an average of 25 years of potential life expectancy compared to current life expectancy in the general population. (Table 1) (Colton & Manderscheid, 2006).

Year	Arizona	Missouri	Oklahoma	Rhode Island	Texas	Utah	Virginia
1997		26.3	25.1		28.5		
1998		27.3	25.1		28.8	29.3	15.5
1999	32.2	26.8	26.3		29.3	26.9	14.0
2000	31.8	27.9		24.9			13.5

Table 1. Mean Number of Years of Potential Life Lost (YPLL) per Public Mental Health Client Who Died During a Year in Which a Service Was Received (modified from Colton & Manderscheid, 2006)

Modifiable Risk Factors	Estimated Prevalence & Relative Risk (RR)	
	Schizophrenia	Bipolar Disorder
Obesity	45-55%, RR: 1.5-2	21-49%, RR: 1-2
Smoking	50-80%, RR: 2-3	54-68%, RR: 2-3
Diabetes	10%-15%, RR: 2	8-17%, RR: 1.5-2
Hypertension	19-58%, RR: 2-3	35-61%, RR: 2-3
Dyslipidemia	25-69%, RR: ≤5	23-38%, RR: ≤3
Metabolic Syndrome	37-63%, RR: 2-3	30-49% RR: 1.5-2

Table 2. Estimated prevalence and relative risk of modifiable cardiovascular disease risk factors in patients with schizophrenia and bipolar disorder compared to the general population (modified from Correl, 2007)

This mortality gap has been noted in different study (Saha et al., 2007; Robson & Gray, 2007) even in countries where the quality of the health care system is generally acknowledged to be good (Osby et al., 2000). The excess mortality was attributable to physical illness (Saha et al., 2007; Robson & Gray, 2007), with cardiovascular disease (CVD) being the major contributor (Colton & Manderscheid, 2006). A recent cohort study of primary care patients in the UK has confirmed the increased prevalence of CVD associated with severe mental illness (Osborn, 2007) and different authors agree that cardiovascular illness may partly

explain why patients with schizophrenia die at least 10 years earlier than the general population (Heald et al., 2010; De Hert et al., 2011).

Risk factors for cardiovascular morbidity and mortality in the general population include those that are inherently non-modifiable (gender, age, family history) and those that are modifiable through behavioural changes and improved care (Heald et al., 2010). The differential risk for morbidity and mortality from CVD in patients with schizophrenia and bipolar disorder compared to the general population can be explained by a 1–5-fold (Tab. 2) relative risk for modifiable risk factors for CVD (Correll, 2007). These risk factors include smoking (Hennekens et al., 2005; S. Davidson et al., 2001; Goff et al., 2005; Herran et al., 2004; Ucok et al., 2004), obesity (Hennekens et al., 2005; Fagiolini et al., 2005), diabetes (Fagiolini et al., 2005; Goff et al., 2005; Kilbourne et al., 2004), arterial hypertension (Hennekens et al., 2005; Fagiolini et al., 2005; Goff et al., 2005;), dyslipidemia (Hennekens et al., 2005; Fagiolini et al., 2005; Nasrallah et al., 2006) and metabolic syndrome (Meyer et al., 2005; McEvoy et al., 2005; Cohn et al., 2004; Kato et al., 2004; Heiskanen et al., 2003; Birkenaes et al., 2007; Yumru et al., 2007).

2.1 Metabolic syndrome

With regard to cardiovascular risk in persons with severe mental illness, of most concern is the development of metabolic syndrome (Casey, 2005; Angst et al., 2002). It has also been found in 37% of patients with long-term schizophrenia (Heiskanen et al., 2003) compared with 24% in the general population and after adjusting for age, these data suggest that persons with schizophrenia have double the incidence of the metabolic syndrome compared with the general population (Ford et al., 2002). Metabolic syndrome rates in patients with bipolar disorder and schizoaffective disorder have been reported to be 30–49% (Fagiolini et al., 2005; Pacholczyk et al., 2008; De Hert et al., 2011) and 42% (Basu et al., 2004), respectively.

With the metabolic syndrome, individuals have approximately a 5–6 fold increased risk of developing diabetes and a 3–6 fold increased risk of mortality due to coronary heart disease (Grundy, 2006; Hanson et al., 2002; Laaksonen et al., 2002, Fagiolini et al., 2005; Li & Ford, 2006; Bhargava, 2003; Grundy, 2006; Pacholczyk et al., 2008). In a study of 3606 general population subjects (Isomaa et al., 2001) over a median follow-up of 6.9 years, the presence of the syndrome was associated with significantly higher all-cause mortality (18.0% versus 4.6%; $p < 0.001$) and cardiovascular mortality (12.0% versus 2.2%; $p < 0.001$).

Despite several definitions of the metabolic syndrome have been proposed over the years (Tab. 3), there is agreement that the major characteristics of the syndrome include central obesity, hypertension, dyslipidemia, glucose intolerance or insulin resistance (Li and Ford, 2006; Grundy et al., 2005; De Hert et al., 2011).

Alarmingly, the metabolic syndrome risk appears to be relatively highest in younger patients, which is likely to be responsible for the dramatically reduced life expectancy (Colton and Manderscheid, 2006), with an increased risk over the course of the illness (Fig.1). In a cross-sectional study (Graph.1) metabolic syndrome rate, using NCEP ATP III definition, for first-episode patients (<1.5 years) was 17%; for recent onset patients (1.5– 10 years) it was 21.5%; for subchronic patients (10–20 years) it was 34.9%; and for chronic patients (>20 years) it was 36.7% (De Hert M et al., 2006).


Criteria	NCEP ATP III (2001)	NCEP ATP III A (2004)	IDF (2005)	IDF & AHA/NHLBI (2009)
Required factor	None but any 3 or more of the following	None but any 3 or more of the following	Central obesity plus any 2 of the following	None but any 3 or more of the following
Additional factors				
Obesity	waist circumference ≥ 102 cm (men) ≥ 88 cm (women)	waist circumference ≥ 102 cm (men) ≥ 88 cm (women)		Elevated waist circumference and country-specific definitions as defined by the IDF and AHA/ NHLBI until more data are available
Triglycerides	≥ 150 mg/dL (≥ 1.7 mmol/L) or on elevated triglycerides Rx	≥ 150 mg/dL (≥ 1.7 mmol/L) or on elevated triglycerides Rx	≥ 150 mg/dL (≥ 1.7 mmol/L) or on lipid abnormality Rx	≥ 150 mg/dL (≥ 1.7 mmol/L) (Rx for elevated triglycerides is an alternate indicator)
HDL - cholesterol	< 40 mg/dL (< 1.03 mmol/L)(men) < 50 mg/dL (< 1.29 mmol/L) (women) or on reduced HDL-cholesterol Rx	< 40 mg/dL (< 1.03 mmol/L)(men) < 50 mg/dL (< 1.29 mmol/L) (women) or on reduced HDL-cholesterol Rx	< 40 mg/dL (< 1.03 mmol/L)(men) < 50 mg/dL (< 1.29 mmol/L) (women) or on lipid abnormality Rx	< 40 mg/dL (< 1.0 mmol/L)(men) < 50 mg/dL (< 1.3 mmol/L) (women) (Rx for reduced HDL-cholesterol is an alternate indicator)
Blood pressure	$\geq 130/85$ mm Hg or on hypertension Rx	$\geq 130/85$ mm Hg or on hypertension Rx	$\geq 130/85$ mmHg or on antihypertensive Rx	$\geq 130/85$ mm Hg (antihypertensive Rx in a patient with a history of hypertension is an alternate indicator)
Glucose	≥ 110 mg/dL (≥ 6.1 mmol/L) (includes diabetes mellitus) or on elevated glucose Rx	≥ 100 mg/dL (≥ 5.6 mmol/L) (includes diabetes mellitus) or on elevated glucose Rx	≥ 100 mg/dL (≥ 5.6 mmol/L) or previously diagnosed type 2 diabetes mellitus	≥ 100 mg/dL (≥ 5.6 mmol/L) (Rx of elevated glucose is an alternate indicator)

NCEP ATP III: Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)

IDF: International Diabetes Federation

AHA/NHLBI: American Heart Association/National Heart, Lung, and Blood Institute

Table 3. Definitions of the metabolic syndrome (modified from De Hert et al., 2011)



Graphic 1. Metabolic syndrome prevalence over the disease course of schizophrenia (modified from De Hert M et al., 2006)


2.2 Diabetes

Currently, 70% of people with diabetes live in developing countries, and while diabetes is increasing across the world, its greatest increase will be in these countries (De Hert et al., 2011). By 2030 more than 80% of people with diabetes mellitus will live in developing countries (Whiting et al., 2010). Persons with diabetes have an increased risk of CVD, and CVD is the cause of death in 70% to 80% of these individuals (Sicree et al., 2003). Evidence suggests that the prevalence of diabetes in people with schizophrenia as well as in people with bipolar disorder and schizoaffective disorder is 2-3 fold higher compared with the general population (Bushe and Holt, 2004;).

The reason for the increased risk of diabetes mellitus in patients with major mental disorder is multifactorial and includes genetic and lifestyle factors as well as disease and treatment specific effects (Fig. 1). An increase in well-established diabetes risk factors in these patients partially accounts for much of the increased risk (De Hert et al., 2011). However, additional factors (disease, treatment) are important as well, and research suggests that, compared to the general population (De Hert M et al., 2006), the prevalence of diabetes in schizophrenia patients is 4 to 5 times higher in different age groups (Graph. 2).

In the general population two important factors that contribute to the development of diabetes are insulin resistance and obesity (Fig. 1). The link between obesity and diabetes is well established (Heald, 2010). A 10 year follow-up study has shown that people with a body mass index (BMI) of ≥ 35 are approximately 20 times more likely to develop diabetes than age and gender-matched subjects with a BMI of < 25 (Field et al., 2001).

The reasons of an higher prevalence of diabetes in schizophrenia patients over the course of the illness is probably an effect of an increased prevalence of obesity, often attributed to antipsychotic treatment (Montejo, 2010; Mulnier et al., 2006).



Graphic 2. Prevalence of diabetes in schizophrenia patients over the disease course compared to the general population (modified from De Hert M et al., 2006)





Fig. 1. Factors influencing the risk of diabetes among patients with schizophrenia (M. Smith et al., 2008)

2.3 Obesity

Obesity is becoming a significant and growing health crisis, affecting both developed and developing countries (Haslam & James, 2005; De Hert et al., 2011). People with obesity have shorter life spans and are at increased risk for a number of general medical conditions, including type 2 diabetes mellitus, diabetes mellitus (relative risk, RR >3), cardiovascular disease, CVD (RR >2-3), dyslipidemia (RR >3), hypertension (RR >2-3), respiratory difficulties (RR >3), reproductive hormone abnormalities (RR >1-2) and certain cancers (e.g., colon) (RR >1-2) (McElroy, 2009; Bray & Wilson, 2008). Levels of obesity are higher in those with schizophrenia and depression, as well as the mortality from obesity-related conditions such as coronary heart disease (Allison et al., 2009). Increasing evidence suggests that persons with major mental disorder are, compared to the general population, at increased risk for overweight and obesity (Graph. 3) (Allison et al., 1999; Dickerson et al, 2006).



Graphic 3. BMI distributions in schizophrenia patients and the general population (Allison et al., 1999)

This excess prevalence, however, has not been reported consistently in the past. Despite some early reports of obesity in the pre-antipsychotic era (Kraepelin, 1919), classical descriptions of schizophrenia refer to a thin 'neurasthenic' body habitus and many people with first-episode psychosis are not overweight (Green et al., 2006; Lieberman et al., 2003). Some recent studies show that drug-naïve schizophrenia does not present with higher rates of obesity and metabolic problems than a normal population with comparable lifestyle (Padmavati et al., 2010; Verma et al., 2009). Taken together these findings suggest that other factors such as treatment or lifestyle factors may be play an important role in the development of weight gain in these patients over the course of the illness.

2.4 Dyslipidemia

Any increase in cholesterol levels has significant health implications, as a 10% increase in cholesterol levels is associated with a 20% to 30% increase in the risk of coronary heart disease (LaRosa et al., 1990).

Elevated fasting triglycerides (TG) are a direct result of insulin resistance, because insulin-dependent lipases in fat cells are normally inhibited by insulin (Stahl et al., 2009). As insulin resistance worsens, inappropriately high levels of lipolysis lead to the release of excess amounts of free fatty acids that are hepatically transformed into TG (D.A. Smith, 2007). Elevated fasting TG levels thus become a sensitive marker of insulin resistance, with fasting TG to high density lipoprotein (HDL) ratios (TG : HDL) ≥ 3.0 performing better than fasting glucose in predicting insulin resistance (McLaughlin et al., 2003).


While fasting TG values provide important information on insulin resistance, fasting TG and especially non-fasting TG, also correlate with cardiovascular risk. recent studies indicate that nonfasting TG may be more important for the development of atherosclerotic arterial injury and subsequent CV risk.

The basis of this assertion lies in the concept that arterial injury may occur primarily during the postprandial period, when TG-rich particles are at their highest level and penetrate arterial intimal cells (Eberly et al., 2003). Results of a large (n = 13 981) European trial with extensive follow-up (mean 26 years), indicate a significant correlation between non-fasting TG levels and risk of major cardiovascular events (Nordestgaard et al., 2007).

3. Treatments exacerbate cardiometabolic risk factors

In addition to increased vulnerability to developing physical health problems, it has also been reported that side-effects of antipsychotic drugs have been linked to other physical health conditions such as weight gain, diabetes, and dyslipidaemia (Bobes et al., 2010). Equally, antidepressants (AD) such as paroxetine (Fava et al., 2006), and mood stabilizers, such as lithium and valproate (Bowden et al., 2000), have been associated with weight gain.

While first-generation antipsychotics (FGAs) might also lead to weight gain, especially the less frequently used low-potency FGAs, certain second-generation antipsychotics (SGAs) are now known to induce much greater weight gain (Graph. 4) and cardiometabolic changes in certain patients (Leucht et al., 2009).



Graphic 4. Effect of second generation versus first-generation antipsychotic on weight gain (modified from Leucht et al., 2009)

Of these agents, clozapine and olanzapine are generally associated with the greatest impact on body weight during both shorter- and longer-term (Leucht et al., 2009) therapy. Data suggest that risperidone has an intermediate effect on weight in the short term, and quetiapine appears to have a short-term weight gain potential similar to that of risperidone (Leucht et al., 2009). By comparison, the newer antipsychotic agents, aripiprazole and ziprasidone, are associated with minimal weight gain (Leucht et al., 2009).

The paliperidone extended release, the active metabolite of risperidone, has the same weight gain profile as its parent drug (M. Davidson et al., 2007).

No agent, however, should be considered as truly weight-neutral, as the proportion of individuals experiencing $\geq 7\%$ weight gain is greater with any SGAs than with placebo (Citrome, 2007), and all antipsychotics have been found to cause significant weight gain in antipsychotics naïve or first-episode patients (Alvarez-Jiménez et al., 2008; Correll et al., 2009; Saddichha et al., 2007) (Tab. 4).

Another important issue is that the weight gain during treatment with antipsychotics occurs in the first weeks (4-6), therefore careful monitoring is necessary to start from the beginning of treatment (Jones et al., 2001; Kinon et al., 2005).

Drug	Weight gain	Glucose effects	Lipid effects	QTc prolongation
Clozapine	+++	+++	+++	0
Olanzapine	+++	+++	+++	0
Risperidone	++	++	++	+
Quetiapine	++	++	++	0
Amisulpride	+	+	+	0
Aripiprazole	0	0	0	0
Ziprasidone	0	0	0	++
Paliperidone	++	0	0	0
Sertindole	++	++	++	++
Zotepine	+++	+++	+++	+
Haloperidol	+	0	0	+ (IV)

0 = no risk or rarely causes side effects at therapeutic dose, + = mild or occasionally causes side effects at therapeutic dose, ++ = sometimes causes side effects at therapeutic dose, and +++ = frequently causes side effects at therapeutic dose.

Table 4. Cardiometabolic side effects of antipsychotics (modified from Marder et al., 2004)

Although the mechanisms underlying weight gain are still unknown after initiation of antipsychotic treatment, a strong increase of appetite is combined with immediate substantial weight gain (Theisen et al., 2003; Gebhardt et al., 2007). The level of H1 antagonism associated with different antipsychotic medications is hypothesized to modulate feeding behavior (increased appetite and decreased sensation of satiety), based on the significant association of weight gain and the binding affinity for this receptor. Antipsychotics with minimal affinity for H1 receptors, such as aripiprazole, ziprasidone, and haloperidol, are associated with limited weight gain, while antipsychotics with a high affinity for H1 receptors, such as clozapine, olanzapine, thioridazine, and chlorpromazine, are associated with clinically significant increases in weight (Newcomer, 2005).

Serotonin 2C receptors have been another area of focus, based on data derived from mice with the 5HT_{2C} gene “knocked out” (Stahl et al., 2009). The combined blockade of H1 and

5HT_{2C} receptors has been especially associated with weight gain – sometimes profound – and could explain why atypical antipsychotics such as olanzapine and clozapine, which have high 5HT_{2C} as well as H₁ affinities, might have greater weight gain liabilities than an agent such as chlorpromazine, which lacks appreciable 5HT_{2C} effects, even though it has H₁ antagonist properties (Cutler et al., 2008; Kroeze et al., 2003).

The high interindividual variability in medication-induced weight gain suggests that genetic factors influence the risk to gain weight (Holt and Peveler, 2009).

Studies of genetic predictors of weight gain under antipsychotic therapy have mainly but not exclusively (Vehof et al., 2010) focused on HTR_{2C} (Mulder et al., 2007; Opgen-Rhein et al., 2010) and LEPR (Opgen-Rhein et al., 2010; Gregoor et al., 2009) gene polymorphisms.

Second generation antipsychotics seem also to have a stronger diabetogenic risk than first generation antipsychotics (Scheen and De Hert, 2007; Okumura et al., 2010; Citrome et al., 2007), the risk being 1.3 fold higher in people with schizophrenia taking SGAs compared with those receiving FGAs (M. Smith et al., 2008). However, the risk of diabetes-related adverse events differs between SGAs. Specifically olanzapine (Ramaswamy et al., 2006; Yood et al., 2008; Koller & Doraiswamy, 2002; Starrenburg & Bogers, 2009) and clozapine (Yood et al., 2008; Starrenburg & Bogers, 2009; Koller et al., 2001) and, to a lesser extent, quetiapina (Koller et al., 2004) and risperidone (Koller et al., 2003), are associated with an increased risk of diabetes (Strassnig et al., 2003) in people who have schizophrenia or bipolar disorder (Guo et al., 2007; Guo et al., 2006). A recent large-scale pharmacoepidemiologic study (including 345,937 patients) found low to moderate, but significantly increased rates of incident DM compared with the general population for clozapine (RR=1.45), olanzapine (RR=1.29) and risperidone (RR=1.23). Rates increased two or more times with ziprasidone and sertindole. Aripiprazole, amisulpride and quetiapina did not have a significantly increased rate (Kessing et al., 2010).

Other psychotropic drugs such as antidepressants may also increase the risk of diabetes mellitus, probably partly due to side effects such as sedation, increased appetite, and weight gain (Sussman et al., 2001; L.C. Brown et al., 2008). Given the heterogeneity and small sample sizes of the few currently available studies, it is unclear whether or not specific antidepressants themselves may increase the risk of diabetes mellitus. Nevertheless, it seems that an increased risk of diabetes is associated with the concurrent use of tricyclic antidepressants and serotonin reuptake inhibitors (SSRIs) (OR=1.89) (L.C. Brown et al., 2008), the long-term use of both tricyclic antidepressants (incidence rate ratio, IRR=1.77) and SSRIs (IRR=2.06) in at least moderate daily doses (Andersohn et al., 2009), as well as the use of antidepressant medication in high-risk patients (Rubi net al., 2008). Furthermore, although understudied, certain mood stabilizers, especially valproate, have been associated with an elevated risk for the development of insulin resistance (Verrotti et al., 2009; Pylvänen et al., 2006), conferring a risk for diabetes mellitus, which is possibly related to weight gain (Masuccio et al., 2010), and/or fatty liver infiltration (Luef et al., 2004), but also to valproate itself (Pylvänen et al., 2002).

Additionally to weight gain and diabetes, some SGAs cause hypertriglyceridaemia, which is an independent risk factor of coronary arteriosclerosis (Tschoner et al., 2007). A prospective study comparing the effects of the SGAs clozapine, olanzapine, risperidone and the FGA sulpiride on glucose and lipid metabolism in first-episode schizophrenia at baseline and 8 weeks after inclusion showed that besides higher C-peptide, fasting insulin and insulin resistance index (IRI), cholesterol and triglyceride levels were significantly increased in the clozapine and olanzapine groups (Wu et al., 2006). Because of these results the authors

recommend that baseline and 6-month monitoring of fasting blood glucose, fasting cholesterol and triglyceride levels should be obtained in routine clinical practice with all antipsychotics to monitor the risk for development of hyperglycaemia and hypercholesterolaemia. Another study described a negative effect of olanzapine administration on total cholesterol and triglycerides, whereas favourable metabolic effects were observed in ziprasidone-treated patients with regard to total cholesterol, LDL and HDL (R.R. Brown & Estoup, 2005). These results were confirmed in different studies (Lieberman et al., 2005; Rettenbacher et al., 2006) and the authors suggest ziprasidone as a favourable alternative treatment for already overweight patients.

In the assessment of cardiometabolic risk, in recent years, particular attention has been paid to the ability of psychotropic drugs to prolong the corrected QT (QTc) interval, which may result in torsades de pointes and sudden cardiac death (Glassman, 2005; Zareba, 2007). An increasing number of psychotropic drugs, are known to delay cardiac repolarization and to induce torsade de pointes. Antipsychotic drugs have a dose-dependent effect on the myocardial repolarization by inhibiting the delayed potassium rectifier current (IKr) (Yap & Camm, 2003). There is a consensus that QTc values >500 msec, or an absolute increase of 60 msec compared with drug-free baseline, puts a patient at significant risk of torsade de pointes, ventricular fibrillation and sudden cardiac death (Haddad and Sharma, 2007; Pies, 2001; Elbe & Savage, 2010). Most antipsychotics and some antidepressants may be associated with QTc prolongation (Glassman, 2005). Patients using AP have higher rates of cardiac arrest or ventricular arrhythmias than controls, with ratios ranging from 1.7 to 5.3 (Ray et al., 2001; Hennessy et al., 2002; Reilly et al., 2002). Antipsychotics associated with a greater risk of QTc prolongation include pimozide, thioridazine and mesoridazine among the FGAs (Vieweg, 2002; Reilly et al., 2002) and sertindole and ziprasidone among the SGAs (Thomas et al., 2010). However, the largest randomized study to date (n=18,154) did not find a statistically significant difference in the risk of sudden cardiac death between ziprasidone and olanzapine treated patients with schizophrenia (Strom et al., 2011).

3.1 The time of monitoring

The maintenance of physical health is an important factor in the successful global management of schizophrenia patients. Research studies have continued to draw attention to monitoring the physical health of patients with schizophrenia in order to successfully enhance these individuals' quality of life (Nasrallah, 2005). In the past decades physical health monitoring of patients with severe mental disorder looked for the extrapyramidal symptoms and tardive dyskinesia often associated with conventional antipsychotics. Atypical antipsychotics were developed to overcome extrapyramidal side effects associated with the use of typical antipsychotics at clinically effective doses, and this has led to widespread use since their introduction over a decade ago (Balf et al., 2008). Despite these benefits, the use of second generation antipsychotics has also been associated with reports of dramatic weight gain, diabetes and atherogenic lipid profiles (Newcomer et al., 2002).

Over recent years, both national and international groups have developed screening and monitoring guidelines (ADA, 2004; De Hert et al., 2009). These guidelines are based on the principle that it is particularly important to establish baseline CVD risk at initial presentation so that any subsequent change during treatment can be monitored. The medical history and examination should therefore include: history of previous CVD, diabetes or other related disease; family history of premature CVD, diabetes or other related

disease; smoking habit; weight and height in order to calculate body mass index (BMI) and waist circumference; fasting blood glucose; fasting blood lipids: total cholesterol, triglycerides, LDLcholesterol (by calculation) and HDL-C; blood pressure (measured twice and average taken), heart rate, heart and lung auscultation, foot pulses; ECG (De Hert et al., 2009).

	Baseline	Week 1	Week 2	Week 3	Week 4	Week 5	Week 6	Week 12
History of previous CVD or other related disease	X							
Smoking habit	X							
Weight	X	X	X	X	X	X	X	X
Height	X							
Waist circumference	X	X						
Fasting blood glucose	X						X	X
Total cholesterol	X						X	X
Triglycerides	X						X	X
LDL-C	X						X	X
HDL-C	X						X	X
Blood pressure	X							
ECG	X		X					

Table 5. Screening and monitoring of cardiovascular disease risk factors (modified from De Hert et al., 2009).

It is recommended that measurements should be taken at the initial presentation and before the first prescription of antipsychotic medication (Tab. 5). The frequency of testing will depend on the patient's medical history and the prevalence of baseline risk factors. For patients with normal baseline tests, it is recommended that biochemical measurements are repeated at 6 weeks and 12 weeks after initiation of treatment and at least annually thereafter. The frequency of testing will depend on the presence of risk factors and detected abnormalities. During the initial phase of treatment, it is important to measure weight weekly to identify those individuals who gain weight rapidly with psychotropic treatment. In patients with diabetes, an assessment of glycaemia control by HbA1c should be made regularly (approximately every 3 months).

The huge amount of data on cardiometabolic side effects of antipsychotics have shifted over the years the attention of the clinicians to a greater perception of cardiometabolic diseases in patient with severe mental illness (Fig. 2) although still several studies indicate that mentally ill patients receive substandard care regarding routine metabolic monitoring (Haupt et al., 2009).

Since the publication of monitoring guidelines in 2004 (ADA 2004) the following recommendations have been generally accepted as the standard of care: assessment of CVD risk factors and all five components of the metabolic syndrome (ie, weight and waist circumference, blood pressure, and fasting glucose and lipids) prior to antipsychotic initiation; weight assessments at each visit (or monthly for the first 3 months and then

quarterly); and assessment of all components of the metabolic syndrome at 3 months and annually. However a retrospective study which evaluated plasma lipid and glucose testing rates in patients receiving second-generation antipsychotics before and after guidelines were published revealed monitoring for plasma lipids and glucose in this population remains low (Haupt et al., 2009).

Reasons are complex and involve patient nonadherence with medical appointments and interventions, suboptimal monitoring and management behaviors of mental and medical health care providers, and systems issues of fragmented care and poor access to care.




Fig. 2. Shift in risk perception of antipsychotics

3.2 Practical issue to reduce cardiometabolic risk

Given the increased incidence of CVD mortality in people with schizophrenia and bipolar disorder, efforts should be made to lower the modifiable risk factors in this population. A reduction in the prevalence of metabolic syndrome is an important target to improve the physical health of patients with severe mental illness (Heald, 2010). If the patient has central obesity, hypertensive blood pressure ($\geq 130/85$ mm Hg), pre-diabetes (fasting plasma glucose $=100-125$ mg/dL or hemoglobin A1C $=5.7-6.4\%$) or DM (fasting plasma glucose ≥ 126 mg/dL or hemoglobin A1C $>6.4\%$), or marked dyslipidemia (total cholesterol >350 mg/dL; LDLcholesterol >160 mg/dL; triglycerides >300 mg/dL), he/she should be referred


to primary care provider to treat these conditions, unless simple healthy lifestyle guidance or behavioural adjustment and/or switching to a lower cardiometabolic risk medication can address these medical conditions adequately (De Hert et al., 2009).

Non-pharmacological interventions, incorporating dietary and physical activity modifications, demonstrated promise in terms of preventing weight gain in schizophrenia (De Nayer et al., 2005; Sáiz Ruiz et al., 2008; Buckley et al., 2005; Haupt et al., 2009; Vreeland, 2007; Faulkner et al., 2007; Alvarez-Jiménez et al., 2008). The impact on one's overall health, even with simple life style changes, is considerable. A healthy diet, regular physical activity and quitting smoking are the key components of lowering the prevalence and impact of modifiable risk factors. However, if lifestyle interventions do not succeed, medication, including statins, anti-hypertensive therapy or antidiabetic agents, may be indicated. These drugs should be prescribed and managed as for the general population and are generally well tolerated (Cormac, 2009; Laurent & Simons, 2009). Moreover, pharmacologic treatments added to reduce antipsychotic-related weight can be tried. To date, most evidence exists for metformin (500 to 1000 mg bid with meals) or topiramate (50-200 mg in divided doses) (Maayan & Correll, 2010).

If these strategies fail, the clinician should consider switching from a medication with a higher weight-gain liability to one with a lower weight gain liability. Ziprasidone and perphenazine treatments in the CATIE trial (Lieberman et al., 2005) were associated with mean weight loss, most likely related to the switch from a previous antipsychotic treatment. Of those patients who had gained > 7% of their body weight in initial phase of the CATIE who were then randomly assigned to ziprasidone in the second phase of the trial (Stroup et al., 2006), 42% lost more than 7% of their body weight; 20% of those randomly assigned to risperidone lost more than 7% of their body weight; and 7% of patients randomly assigned to quetiapina lost 7% of their body weight. None of the patients who gained >7% of their body weight in the initial phase of the study and were then randomly assigned to olanzapine in the subsequent phase lost more than 7% of their body weight. In phase 3 (Stroup et al., 2009), participants selected openly from the following nine possible treatment regimens: antipsychotic monotherapy with oral aripiprazole (ARIP), clozapine (CLOZ), olanzapine (OLAN), perphenazine (PERP), quetiapine (QUET), risperidone (RISP), or ziprasidone (ZPR); long-acting injectable fluphenazine decanoate (Flu-D); or a combination of any two of these treatments (Comb). If the selected treatment was not discontinued because of inadequate efficacy, intolerability, or any other reason, patients could continue taking this regimen until the completion of 18 months of study treatment. Of the common choices, those who selected aripiprazole and ziprasidone had the highest body mass index and the most monthly weight loss was associated with aripiprazole and ziprasidone (Graph. 5).

Clinicians should consider switching antipsychotics when there is a clear relationship between antipsychotic exposure and change in healthrisk category (i.e., obesity, diabetes, sleep apnea), the patient is about to stop or has stopped antipsychotic use because of weight gain, the patient has bulimia or the patient is abusing weight loss drugs due to newly developed weight gain on antipsychotic treatment. Current evidence (Weiden, 2007) indicates that switching is an effective strategy primarily in patients whose weight gain is attributable to preswitch antipsychotic and in whom long-term monotherapy with a weight-neutral agent can be maintained. In this population, the effectiveness of switching appears to be related to a reversal of the weight-increasing effects of a prior antipsychotic medication.

Regarding the effect of antipsychotics on the QTc interval, the use of lower doses and monotherapy may represent an effective strategy in reducing the risk of QTc lengthening (Di Sciascio et al., 2011).



Graphic 5. Weight change among the commonly selected treatments in Phase 3 of CATIE (Stroup et al., 2009)

4. Conclusion

The mortality gap between patients with severe mental illness and the general population has substantially widened in recent decades, warranting close attention to the cardiovascular health of this patient population. Reasons for the increased prevalence rates of CHD risk factors are complex, but include effects of mental illness, poor lifestyle behaviors, weight gain, and metabolic abnormalities conferred by psychiatric treatments, particularly by SGAs. While the mechanisms for weight gain are still unclear and direct, weight-independent mechanisms for at least some SGAs regarding glucose and lipid abnormalities have been discussed, it is clear that antipsychotics differ in their risk for adverse changes in body weight and metabolic dysregulation (Correll, 2007).

As individuals with mental illness are more likely to be overweight or obese than the general population, weight should be routinely monitored in all patients, especially in those receiving treatment with atypical antipsychotic medications associated with weight gain (Balf et al., 2008).

Routine adverse-effect monitoring should be part of any pharmacologic treatment. For antipsychotics, this should include baseline assessments of EPS and abnormal involuntary movements, sleep duration and quality, daytime sedation, sexual and reproductive dysfunction, and risk factors for cardiovascular disease, including unhealthy lifestyle (Correll, 2007).

By using the charts and tables in this article, clinicians will be better informed to educate the patient in a variety of interventions that will diminish the potential for medication side effects, promote better pharmacologic efficacy from prescribed medications, and improve the overall quality of life.

In conclusion, the management of patients at risk of cardiometabolic disease can be complex, but if performed systematically and in conjunction with healthcare professionals

who can address the metabolic complications in a complementary fashion, it can provide a clinical outcome that will be potentially very beneficial to the individual patient. The reintegration of psychiatric care and general somatic services seems to represent one of the most important challenges for psychiatric care today.

5. Acknowledgment

The authors would like to thank Scientific Board of the Società Italiana di Psichiatria, Sezione Puglia e Basilicata, the who contributed to the development of this article.

6. References

- Alberti KG, Zimmet P, Shaw J. The metabolic syndrome-a new worldwide definition. *Lancet* 2005;366:1059-62.
- Allison DB, Fontaine KR, Heo M, Mentore JL, Cappelleri JC, Chandler LP, Weiden PJ, Cheskin LJ. The distribution of body mass index among individuals with and without schizophrenia. *J. Clin. Psychiatry* 1999;60 (4):215-220.
- Allison DB, Newcomer JW, Dunn AL, Blumenthal JA, Fabricatore AN, Daumit GL, Cope MB, Riley WT, Vreeland B, Hibbeln JR, Alpert JE. Obesity among those with mental disorders: a National Institute of Mental Health meeting report. *Am J Prev Med.* 2009;36(4):341-5
- Alvarez-Jiménez M, González-Blanch C, Crespo-Facorro B et al. Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal. *CNS Drugs* 2008;22:547-62.
- Alvarez-Jiménez M, Hetrick SE, González-Blanch C et al. Nonpharmacological management of antipsychotic-induced weight gain: systematic review and meta-analysis of randomised controlled trials. *Br J Psychiatry* 2008;193:101-7.
- American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. *Diabetes Care.* 2004;27(2):596-601.
- Andersohn F, Schade R, Suissa S et al. Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus. *Am J Psychiatry* 2009;166:591-8.
- Angst F, Stassen HH, Clayton PJ, Angst J. Mortality of patients with mood disorders: follow-up over 34-38 years. *J Affect Disord.* 2002; 68:167-181.
- Balf G, Stewart TD, Whitehead R, Baker RA. Metabolic adverse events in patients with mental illness treated with antipsychotics: a primary care perspective. *Prim Care Companion J Clin Psychiatry.* 2008;10(1):15-24.
- Barnett AH, Mackin P, Chaudhry I et al. Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia. *J Psychopharmacol* 2007;21:357-73.
- Basu R, Brar JS, Chengappa KN et al. The prevalence of the metabolic syndrome in patients with schizoaffective disorder-bipolar subtype. *Bipolar Disord* 2004;6:314-8.
- Bhargava A. A longitudinal analysis of the risk factors for diabetes and coronary heart disease in the Framingham Offspring Study. *Popul Health Metr* 2003;1:3.

- Birkenaes AB, Opjordsmoen S, Brunborg C, et al. The level of cardiovascular risk factors in bipolar disorder equals that of schizophrenia: a comparative study. *J Clin Psychiatry*. 2007;68(6):917-923.
- Bobes J, Arango C, Garcia-Garcia M, Rejas J. Healthy lifestyle habits and 10-year cardiovascular risk in schizophrenia spectrum disorders: an analysis of the impact of smoking tobacco in the CLAMORS schizophrenia cohort. *Schizophr Res* 2010 ;119(1-3):101-9..
- Bowden CL, Calabrese JR, McElroy SL et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. *Arch Gen Psychiatry* 2000;57:481-9.
- Bray GA, Wilson JF. In the clinic. Obesity. *Ann Intern Med* 2008;149:ITC4-1-15.
- Brown LC, Majumdar SR, Johnson JA. Type of antidepressant therapy and risk of type 2 diabetes in people with depression. *Diabetes Res Clin Pract* 2008;79:61-7.
- Brown RR, Estoup MW. Comparison of the metabolic effects observed in patients treated with ziprasidone versus olanzapine. *Int Clin Psychopharmacol* 2005; 20: 105-12.
- Buckley PF, Miller DD, Singer B et al. Clinicians' recognition of the metabolic adverse effects of antipsychotic medications. *Schizophr Res* 2005;79:281-8.
- Bushe C, Holt R. Prevalence of diabetes and impaired glucose tolerance in patients with schizophrenia. *Br J Psychiatry* 2004; 47:S67-S71.
- Casey DE. Metabolic issues and cardiovascular disease in patients with psychiatric disorders. *The American Journal of Medicine*. 2005;118(S2):15-22.
- Citrome LL. Risk-benefit analysis of available treatments for schizophrenia. *Psychiatric Times* 2007;1:27-30.
- Citrome LL, Holt RI, Zachry WM et al. Risk of treatment-emergent diabetes mellitus in patients receiving antipsychotics. *Ann Pharmacother* 2007;41:1593-603.
- Cohn T, Prud'homme D, Streiner D, et al. Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. *Can J Psychiatry*. 2004;49(11):753-760.
- Colton CW, Manderscheid RW. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. *Prev Chronic Dis*. 2006 Apr;3(2):A42.
- Cormac I. Promoting healthy lifestyles in psychiatric services. In: *Physical health in mental health*. Final report of a scoping group. Royal College of Psychiatrists, 2009:62-70.
- Correll CU. Balancing efficacy and safety in treatment with antipsychotics. *CNS Spectr*. 2007 Oct;12(10 Suppl 17):12-20, 35.
- Correll CU, Manu P, Olshanskiy V et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. *JAMA* 2009;302:1765-73.
- Cutler AC, Ball S, Stahl SM. Dosing atypical antipsychotics. *CNS Spectr* 2008;13(Suppl. 9):1-16.
- Davidson M, Emsley R, Kramer M, et al. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. *Schizophr Res* 2007;93(1-3):117-130.
- Davidson S, Judd F, Jolley D, et al. Cardiovascular risk factors for people with mental illness. *Aust N Z J Psychiatry*. 2001;35(2):196-202.

- De Hert M, van Winkel R, Van Eyck D, et al. Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study. *Clin Pract Epidemiol Ment Health*. 2006;27(2):14.
- De Hert M, Dekker JM, Wood D, Kahl KG, Holt RI, Möller HJ. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). *Eur Psychiatry*. 2009 Sep;24(6):412-24.
- De Hert M, Correll CU, Bobes J, Cetkovich-Bakmas M, Cohen D, Asai I, Detraux J, Gautam S, Möller HJ, Ndeti DM, Newcomer JW, Uwakwe R, Leucht S. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. *World Psychiatry*. 2011;10(1):52-77.
- De Nayer A, De Hert M, Scheen A et al. Belgian consensus on metabolic problems associated with atypical antipsychotics. *Int J Clin Pract* 2005;9:130-7.
- Dickerson FB, Brown CH, Daumit GL, et al. Health status of individuals with serious mental illness. *Schizophr Bull* 2006;32:584-9.
- Di Sciascio G, Calo S, Amodio G, D'Onofrio S, Pollice R. The use of first generation versus second generation antipsychotics as add-on or as switch treatment and its effect on QTC interval: the Italian experience in a real-world setting. *Int J Immunopathol Pharmacol*. 2011 Jan-Mar;24(1):225-30
- Eberly LE, Stamler J, Neaton JD, Multiple Risk Factor Intervention Trial Research G. Relation of triglyceride levels, fasting and nonfasting, to fatal and nonfatal coronary heart disease. *Arch Intern Med* 2003;163:1077-1083.
- Elbe D, Savage R. How does this happen? Part I: mechanisms of adverse drug reactions associated with psychotropic medications. *J Can Acad Child Adolesc Psychiatry* 2010;19:40-5.
- Expert Panel on Detection and Evaluation of Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). *JAMA* 2001;285:2486-97.
- Fagiolini A, Frank E, Scott JA et al. Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians. *Bipolar Disord* 2005;7:424-30.
- Faulkner G, Cohn T, Remington G. Interventions to reduce weight gain in schizophrenia. *Schizophr Bull* 2007;33:654-6.
- Fava M, Judge R, Hoog SL et al. Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment. *J Clin Psychiatry* 2000;61:863-7.
- Field AE, Coakley EH, Must A, Spadano JL, Laird N, Dietz WH, et al. Impact of overweight on the risk of developing common chronic diseases during a 10-year period. *Arch Intern Med* 2001;161:1581-6.
- Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. *JAMA*. 2002;287:356 -359.
- Frye RL. Optimal care of patients with type 2 diabetes mellitus and coronary artery disease. *Am J Med*. 2003;115(suppl 8A):S93-S98.

- Gebhardt S, Haberhausen M, Krieg JC, Remschmidt H, Heinzl-Gutenbrunner M, Hebebrand J, et al. Clozapine/olanzapine-induced recurrence or deterioration of binge eating-related eating disorders. *Journal of Neural Transmission* 2007;114:1091-5.
- Glassman AH. Schizophrenia, antipsychotic drugs, and cardiovascular disease. *J Clin Psychiatry*. 2005;66 Suppl 6:5-10
- Goff DC, Sullivan LM, McEvoy JP, et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. *Schizophr Res*. 2005;80(1):45-53.
- Green AI, Lieberman JA, Hamer RM et al. Olanzapine and haloperidol in first episode psychosis: two-year data. *Schizophr Res* 2006; 86: 234-243.
- Gregoor JG, van der Weide J, Mulder W et al. Polymorphisms of the LEP- and LEPR gene and obesity in patients using antipsychotic medication. *J Clin Psychopharmacol* 2009;26:21-5.
- Grundy SM, Cleeman JI, Daniels SR et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. *Circulation* 2005;112:2735-52.
- Grundy SM, Cleeman JI, Daniels SR et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/ National Heart, Lung, and Blood Institute Scientific Statement. *Circulation* 2005;112:2735-52.
- Grundy SM. Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. *J Am Coll Cardiol* 2006;47: 1093-100.
- Guo JJ, Keck PE Jr, Corey-Lisle PK et al. Risk of diabetes mellitus associated with atypical antipsychotic use among patients with bipolar disorder: a retrospective, population-based, case-control study. *J Clin Psychiatry* 2006;67:1055-61.
- Guo JJ, Keck PE Jr, Corey-Lisle PK et al. Risk of diabetes mellitus associated with atypical antipsychotic use among Medicaid patients with bipolar disorder: a nested case-control study. *Pharmacotherapy* 2007;27:27-35.
- Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics; differential risk and clinical implications. *CNS Drugs* 2007;21:911-36.
- Hanson RL, Imperatore G, Bennett PH et al. Components of the "metabolic syndrome" and incidence of type 2 diabetes. *Diabetes* 2002;51:3120-7.
- Haslam DW, James WP. Obesity. *Lancet* 2005;366:1197-209.
- Haupt DW, Rosenblatt LC, Kim E, Baker RA, Whitehead R, Newcomer JW. Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents. *Am J Psychiatry*. 2009 Mar;166(3):345-53.
- Heald A. Physical health in schizophrenia: a challenge for antipsychotic therapy. *Eur Psychiatry*. 2010;25 (2):S6-11.
- Heiskanen T, Niskanen L, Lyytikäinen R, Saarinen PI, Hintikka J. Metabolic syndrome in patients with schizophrenia. *J Clin Psychiatry*. 2003;64:575-579.
- Hennekens CH, Hennekens AR, Hollar D, et al. Schizophrenia and increased risk of cardiovascular disease. *Am Heart J*. 2005;150(6):1115-1121.
- Hennessy S, Bilker WB, Knauss JS et al. Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: cohort study using administrative data. *BMJ* 2002;325:1070.

- Herran A, de Santiago A, Sandoya M, et al. Determinants of smoking behaviour in outpatients with schizophrenia. *Schizophr Res.* 2000;41(2):373-381.
- Holt R, Peveler R. Obesity, serious mental illness and antipsychotic drugs. *Diabetes Obes Metab* 2009;11:665-79.
- International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. Brussels: International Diabetes Federation, 2005.
- Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. *Diabetes Care* 2001;24:683-9.
- Jones B, Basson BR, Walker DJ, Crawford AM, Kinon BJ. Weight change and atypical antipsychotic treatment in patients with schizophrenia. *J Clin Psychiatry.* 2001;62 Suppl 2:41-4.
- Kato MM, Currier MB, Gomez CM, et al. Prevalence of metabolic syndrome in Hispanic and non-Hispanic patients with schizophrenia. *Prim Care Companion J Clin Psychiatry.* 2004;6(2):74-77.
- Kessing LV, Thomsen AF, Mogensen UB et al. Treatment with antipsychotics and the risk of diabetes in clinical practice. *Br J Psychiatry* 2010;197:266-71.
- Kilbourne AM, Cornelius JR, Han X, et al. Burden of general medical conditions among individuals with bipolar disorder. *Bipolar Disord.* 2004;6(5):368-373.
- Kilbourne AM, Post EP, Bauer MS, et al. Therapeutic drug and cardiovascular disease risk monitoring in patients with bipolar disorder. *J Affect Disord.* 2007;102(1-3):145-151.
- Kinon BJ, Kaiser CJ, Ahmed S, Rotelli MD, Kollack-Walker S. Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders. *J Clin Psychopharmacol.* 2005 Jun;25(3):255-8
- Koller EA, Schneider B, Bennett K et al. Clozapine-associated diabetes. *Am J Med* 2001;111:716-23.
- Koller EA, Doraiswamy PM. Olanzapine-associated diabetes mellitus. *Pharmacotherapy* 2002;22:841-52.
- Koller EA, Cross JT, Doraiswamy PM et al. Risperidone-associated diabetes mellitus: a pharmacovigilance study. *Pharmacotherapy* 2003;23:735-44.
- Koller EA, Weber J, Doraiswamy PM et al. A survey of reports of quetiapine associated hyperglycemia and diabetes mellitus. *J Clin Psychiatry* 2004;65:857-63.
- Kraepelin E. Dementia praecox and paraphrenia. Barkley RM (trans.) ed. Edinburgh: E & S Livingstone, 1919; 331.
- Kroeze WK, Hufeisen SJ, Popadak BA et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. *Neuropsychopharmacology* 2003;28:519-526.
- Laaksonen DE, Lakka HM, Niskanen LK et al. Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. *Am J Epidemiol* 2002;156: 1070-7.
- LaRosa JC, Hunninghake D, Bush D, et al. The cholesterol facts: a summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease: a joint statement by the American Heart Association and the National Heart, Lung, and

- Blood Institute. The Task Force on Cholesterol Issues, American Heart Association. *Circulation* 1990; 81(5):1721–1733
- Laurent SM, Simons AD. Sexual dysfunction in depression and anxiety: conceptualizing sexual dysfunction as part of an internalizing dimension. *Clin Psychol Rev* 2009;29:573-85.
- Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. *Lancet*. 2009 Jan 3;373(9657):31-41.
- Li C, Ford ES. Definition of the metabolic syndrome: what's new and what predicts risk? *Metab Syndr Relat Disord* 2006;4:237- 51.
- Lieberman JA, Phillips M, Gu H et al. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. *Neuropsychopharmacology* 2003; 28: 995–1003.
- Lieberman JA, Stroup TS, McEvoy JP et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. *N Engl J Med* 2005; 353: 1209–23.
- Luef GJ, Waldmann M, Sturm W et al. Valproate therapy and nonalcoholic fatty liver disease. *Ann Neurol* 2004;55:729-32.
- Maayan L, Correll CU. Management of antipsychotic-related weight gain. *Expert Rev Neurother* 2010;10:1175-200.
- Maj M. Physical health care in persons with severe mental illness: a public health and ethical priority. *World Psychiatry* 2009;8:1-2.
- Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM, Kane JM, Lieberman JA, Schooler NR, Covell N, Stroup S, Weissman EM, Wirshing DA, Hall CS, Pogach L, Pi-Sunyer X, Bigger JT Jr, Friedman A, Kleinberg D, Yevich SJ, Davis B, Shon S. Physical health monitoring of patients with schizophrenia. *Am J Psychiatry*. 2004 Aug;161(8):1334-49.
- Masuccio F, Verrotti A, Chiavaroli V et al. Weight gain and insulin resistance in children treated with valproate: the influence of time. *J Child Neurol* 2010;25:941-7.
- McElroy SL. Obesity in patients with severe mental illness: overview and management. *J Clin Psychiatry* 2009;70:12-21.
- McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. *Schizophr Res*. 2005;80(1):19-32.
- McIntyre RS, Konarski JZ, Misener VL et al. Bipolar disorder and diabetes mellitus: epidemiology, etiology, and treatment implications. *Ann Clin Psychiatry* 2005;17:83-93.
- McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven G. Use of metabolic markers to identify overweight individuals who are insulin resistant. *Ann Intern Med* 2003;139:802–809.
- Meyer J, Koro CE, L'Italien GJ. The metabolic syndrome and schizophrenia: a review. *Int Rev Psychiatry*. 2005;17(3):173-180.
- Montejo AL. The need for routine physical healthcare in schizophrenia. *Eur Psychiatry* 2010;25:S3-S5.


- Mulder H, Franke B, van der Beek AA et al. The association between HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia. *J Clin Psychopharmacol* 2007;27:338-43.
- Mulnier HE, Seaman HE, Raleigh VS, Soedamah-Muthu SS, Colhoun HM. Mortality in people with Type 2 diabetes in the UK. *Diabet Med* 2006;23:516-21.
- Nasrallah HA. An overview of common medical comorbidities in patients with schizophrenia. *J Clin Psychiatry* 2005;66(Suppl. 6):3-4.
- Nasrallah HA, Meyer JM, Goff DC, et al. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. *Schizophr Res.* 2006;86(1-3):15-22.
- Newcomer JW, Haupt DW, Fucetola R, et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. *Arch Gen Psychiatry* 2002;59(4):337-345.
- Newcomer JW, Nasrallah HA, Loebel AD. The Atypical Antipsychotic Therapy and Metabolic Issues National Survey: practice patterns and knowledge of psychiatrists. *J Clin Psychopharmacol.* 2004;24(5 suppl 1):S1-S6.
- Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. *CNS Drugs* 2005;19 (1):1-93.
- Newman SC, Bland RC. Mortality in a cohort of patients with schizophrenia: a record linkage study. *Can J Psychiatry* 1991;36: 239-245.
- Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. *JAMA* 2007;298:299-308.
- Okumura Y, Ito H, Kobayashi M et al. Prevalence of diabetes and antipsychotic prescription patterns in patients with schizophrenia: a nationwide retrospective cohort study. *Schizophr Res* 2010;119:145-52.
- Opgen-Rhein C, Brandl EJ, Müller DJ et al. Association of HTR2C, but not LEP or INSIG2, genes with antipsychotic-induced weight gain in a German sample. *Pharmacogenomics* 2010;11:773-80.
- Osborn DP, Levy G, Nazareth I, Petersen I, Islam A, King MB. Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Research Database. *Arch Gen Psychiatry* 2007;64:242-9.
- Osby U, Correia N, Brandt L et al. Time trends in schizophrenia mortality in Stockholm county, Sweden: cohort study. *BMJ* 2000; 321:483-4.
- Pacholczyk M, Ferenc T, Kowalski J. The metabolic syndrome. Part I: definitions and diagnostic criteria for its identification. Epidemiology and relationship with cardiovascular and type 2 diabetes risk. *Postepy Hig Med Dosw* 2008;62:530-42.
- Padmavati R, McCreadie RG, Tirupati S. Low prevalence of obesity and metabolic syndrome in never-treated chronic schizophrenia. *Schizophr Res.* 2010;121(1-3):199-202.
- Pies RW. Antipsychotics: the heart of the problem. *Psychiatric Times* 2001;18:26-8.
- Pylvänen V, Knip M, Pakarinen A et al. Serum insulin and leptin levels in valproate-associated obesity. *Epilepsia* 2002;43:514-7.
- Pylvänen V, Pakarinen A, Knip M et al. Insulin-related metabolic changes during treatment with valproate in patients with epilepsy. *Epilepsy Behav* 2006;8:643-8.

- Ramaswamy K, Masand PS, Nasrallah HA. Do certain atypical antipsychotics increase the risk of diabetes? A critical review of 17 pharmacoepidemiologic studies. *Ann Clin Psychiatry* 2006; 18:183-94.
- Ray WA, Meredith S, Thapa PB et al. Antipsychotics and the risk of sudden cardiac death. *Arch Gen Psychiatry* 2001;58:1161-7.
- Regenold WT, Thapar RK, Marano C et al. Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use. *J Affect Disord* 2002;70:19-26.
- Reilly JG, Ayis SA, Ferrier IN et al. Thioridazine and sudden unexplained death in psychiatric in-patients. *Br J Psychiatry* 2002;180:515-22.
- Rettenbacher MA, Ebenbichler C, Hofer A et al. Early changes of plasma lipids during treatment with atypical antipsychotics. *Int Clin Psychopharmacol* 2006; 21: 369-72.
- Robson D, Gray R. Serious mental illness and physical health problems: a discussion paper. *Int J Nurs Stud* 2007;44:457-66.
- Rubin RR, Ma Y, Marrero DG et al. Diabetes Prevention Program Research Group. Elevated depression symptoms, antidepressant medicine use, and risk of developing diabetes during the diabetes prevention program. *Diabetes Care* 2008;31:420-6.
- Ryan MC, Thakore JH. Physical consequences of schizophrenia and its treatment: the metabolic syndrome. *Life Sci.* 2002;71:239-257.
- Sachs GS, Guille C. Weight gain associated with use of psychotropic medications. *J Clin Psychiatry* 1999;60:16-9.
- Saddichha S, Ameen S, Akhtar S. Incidence of new onset metabolic syndrome with atypical antipsychotics in first episode schizophrenia: a six-week prospective study in Indian female patients. *Schizophr Res* 2007;95:247.
- Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia. *Arch Gen Psychiatry* 2007;64:1123-31.
- Sáiz Ruiz J, Bobes García J, Vallejo Ruiloba J et al. Consensus on physical health of patients with schizophrenia from the Spanish Societies of Psychiatry and Biological Psychiatry. *Actas Esp Psiquiatr* 2008;36:251-64.
- Scheen AJ, De Hert MA. Abnormal glucose metabolism in patients treated with antipsychotics. *Diabetes Metab* 2007;33:169- 75.
- Sicree R, Shaw J, Zimmet P. The global burden of diabetes. In Gan D, ed. 2nd ed. *Diabetes Atlas*. Brussels: International Diabetes Federation, 2003.
- Smith DA. Treatment of the dyslipidemia of insulin resistance. *Med Clin North Am* 2007;91:1185-1210.
- Smith M, Hokins D, Peveler R et al. First versus second generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. *Br J Psychiatry* 2008;192:406-11.
- Stahl SM, Mignon L, Meyer JM. Which comes first: atypical antipsychotic treatment or cardiometabolic risk? *Acta Psychiatr Scand* 2009; 119: 171-179.
- Starrenburg FC, Bogers JP. How can antipsychotics cause diabetes mellitus? Insights based on receptor-binding profiles, humoral factors and transporter proteins. *Eur Psychiatry* 2009;24: 164-70.
- Strassnig M, Brar JS, Ganguli R. Body mass index and quality of life in community-dwelling patients with schizophrenia. *Schizophr Res* 2003;62:73-6.

- Strom BL, Eng SM, Faich G, Reynolds RF, D'Agostino RB, Ruskin J, Kane JM. Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC). *Am J Psychiatry*. 2011 Feb;168(2):193-201.
- Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. *Am J Psychiatry* 2006;163(4):611-622.
- Stroup TS, Lieberman JA, McEvoy JP, Davis SM, Swartz MS, Keefe RS, Miller AL, Rosenheck RA, Hsiao JK; CATIE Investigators. Results of phase 3 of the CATIE schizophrenia trial. *Schizophr Res*. 2009;107(1):1-12.
- Suppes T, McElroy SL, Hirschfeld R. Awareness of metabolic concerns and perceived impact of pharmacotherapy in patients with bipolar disorder: a survey of 500 US psychiatrists. *Psychopharmacol Bull*. 2007;40(2):22-37; quiz 38-40.
- Sussman N, Ginsberg DL, Bikoff J. Effects of nefazodone on body weight: a pooled analysis of selective serotonin reuptake inhibitor- and imipramine-controlled trials. *J Clin Psychiatry* 2001;62:256-60.
- Theisen FM, Linden A, König IR, Martin M, Remschmidt H, Hebebrand J. Spectrum of binge eating symptomatology in patients treated with clozapine and olanzapine. *Journal of Neural Transmission* 2003;110:111-21.
- Thomas SH, Drici MD, Hall GC et al. Safety of sertindole versus risperidone in schizophrenia: principal results of the sertindole cohort prospective study (SCoP). *Acta Psychiatr Scand* 2010;122: 345-55.
- Tschoner A, Engl J, Laimer M, Kaser S, Rettenbacher M, Fleischhacker WW, Patsch JR, Ebenbichler CF. Metabolic side effects of antipsychotic medication. *Int J Clin Pract*. 2007 Aug;61(8):1356-70.
- Ucok A, Polat A, Bozkurt O, et al. Cigarette smoking among patients with schizophrenia and bipolar disorders. *Psychiatry Clin Neurosci*. 2004;58(4):434-437.
- van Winkel R, De Hert M, Van Eyck D et al. Screening for diabetes and other metabolic abnormalities in patients with schizophrenia and schizoaffective disorder: evaluation of incidence and screening methods. *J Clin Psychiatry* 2006;67:1493-500.
- van Winkel R, De Hert M, Van Eyck D et al. Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder. *Bipolar Disord* 2008;10:342-8.
- Vehof J, Al Hadithy AFY, Burger H et al. BMI and rs1455832 SNP of the ROBO1 gene: association analysis in patients using antipsychotics. *Schizophr Res* 2010;117:552-3.
- Verma SK, Subramaniam M, Liew A, Poon LY. Metabolic risk factors in drug-naive patients with first-episode psychosis. *J Clin Psychiatry*. 2009 Jul;70(7):997-1000.
- Verrotti A, la Torre R, Trotta D et al. Valproate-induced insulin resistance and obesity in children. *Horm Res* 2009;71:125-31.
- Vieweg WVR. Mechanisms and risks of electrocardiographic QT interval prolongation when using antipsychotic drugs. *J Clin Psychiatry* 2002;63(9):18-24.
- Vreeland B. Treatment decisions in major mental illness: weighing the outcomes. *J Clin Psychiatry* 2007;68:5-11.
- Weiden PJ. Switching antipsychotics as a treatment strategy for antipsychotic-induced weight gain and dyslipidemia. *J Clin Psychiatry*. 2007;68 Suppl 4:34-9.

- Weissman EM, Zhu CW, Schooler NR, et al. Lipid monitoring in patients with schizophrenia prescribed second-generation antipsychotics. *J Clin Psychiatry*. 2006;67(9):1323-1326.
- Whiting D, Unwin N, Roglic G. Diabetes: equity and social determinant. In: Blas E, Sivasankara Kurup A (eds). *Equity, social determinant and public health programmes*. Geneva: World Health Organization, 2010:77-94.
- Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. *Circulation* 1998;97:1837-47.
- Wu RR, Zhao JP, Liu ZN et al. Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. *Psychopharmacology (Berl)* 2006; 186: 572-8.
- Yap YG, Camm AJ. Drug-induced QT prolongation and torsades de pointes. *Heart*. 2003;89:1363-1372.
- Yood MU, DeLorenze G, Quesenberry CP Jr et al. The incidence of diabetes in atypical antipsychotic users differs according to agent - results from a multisite epidemiologic study. *Pharmacoepidemiol Drug Saf* 2009;18:791-9.
- Yumru M, Savas HA, Kurt E, et al. Atypical antipsychotics related metabolic syndrome in bipolar patients. *J Affect Disord*. 2007;98(3):247-522.
- Zareba W. Drug induced QT prolongation. *Cardiol J*. 2007;14(6):523-33.

IntechOpen



Psychiatric Disorders - Worldwide Advances

Edited by Dr. Toru Uehara

ISBN 978-953-307-833-5

Hard cover, 336 pages

Publisher InTech

Published online 03, October, 2011

Published in print edition October, 2011

A psychiatric disorder is defined as any complex condition that involves the impairment of cognitive, emotional, or behavioral functioning. Aside from knowing the physical organic factors, its causal pathology has remained a mystery. Regarding recent advances in psychiatry and neurosciences, psychiatric disorders have been closely associated with socio-cultural, psychological, biochemical, epigenetic or neural-networking factors. A need for diverse approaches or support strategies is present, which should serve as common knowledge, empathetic views or useful skills for specialists in the field. This book contains multifarious and powerful papers from all over the world, addressing themes such as the neurosciences, psychosocial interventions, medical factors, possible vulnerability and traumatic events. Doubtlessly, this book will be fruitful for future development and collaboration in "world psychiatry".

How to reference

In order to correctly reference this scholarly work, feel free to copy and paste the following:

Guido Di Sciascio and Salvatore Calo (2011). The Impact of Cardiometabolic Risk in Patients with Severe Mental Illness: From Evidence to Clinical Management, *Psychiatric Disorders - Worldwide Advances*, Dr. Toru Uehara (Ed.), ISBN: 978-953-307-833-5, InTech, Available from:

<http://www.intechopen.com/books/psychiatric-disorders-worldwide-advances/the-impact-of-cardiometabolic-risk-in-patients-with-severe-mental-illness-from-evidence-to-clinical->

INTECH
open science | open minds

InTech Europe

University Campus STeP Ri
Slavka Krautzeka 83/A
51000 Rijeka, Croatia
Phone: +385 (51) 770 447
Fax: +385 (51) 686 166
www.intechopen.com

InTech China

Unit 405, Office Block, Hotel Equatorial Shanghai
No.65, Yan An Road (West), Shanghai, 200040, China
中国上海市延安西路65号上海国际贵都大饭店办公楼405单元
Phone: +86-21-62489820
Fax: +86-21-62489821

© 2011 The Author(s). Licensee IntechOpen. This is an open access article distributed under the terms of the [Creative Commons Attribution 3.0 License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

IntechOpen

IntechOpen